WEED.TO Quote, Financials, Valuation and Earnings

Core One Labs has a net margin of -203.67% compared to Canopy Growth's net margin of --. Canopy Growth's return on equity of -99.49% beat Core One Labs's return on equity of --.

Canopy Growth has a consensus price target of $6.15, signalling upside risk potential of 48.91%. On the other hand Core One Labs has an analysts' consensus of -- which suggests that it could fall by --. Given that Canopy Growth has higher upside potential than Core One Labs, analysts believe Canopy Growth is more attractive than Core One Labs.

Canopy Growth has a beta of 1.719, which suggesting that the stock is 71.92% more volatile than S&P 500. In comparison Core One Labs has a beta of 0.959, suggesting its less volatile than the S&P 500 by 4.131%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Core One Labs pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $63M, which are larger than Core One Labs quarterly revenues of --. Canopy Growth's net income of -$128.3M is higher than Core One Labs's net income of --. Notably, Canopy Growth's price-to-earnings ratio is -- while Core One Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 1.25x versus 10.48x for Core One Labs. Usually stocks with elevated PS ratios are considered overvalued.

Cronos Group has a net margin of -203.67% compared to Canopy Growth's net margin of 24.37%. Canopy Growth's return on equity of -99.49% beat Cronos Group's return on equity of -4.37%.

Canopy Growth has a consensus price target of $6.15, signalling upside risk potential of 48.91%. On the other hand Cronos Group has an analysts' consensus of -- which suggests that it could grow by 23.82%. Given that Canopy Growth has higher upside potential than Cronos Group, analysts believe Canopy Growth is more attractive than Cronos Group.

Canopy Growth has a beta of 1.719, which suggesting that the stock is 71.92% more volatile than S&P 500. In comparison Cronos Group has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.184%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cronos Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Cronos Group pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $63M, which are larger than Cronos Group quarterly revenues of $46.7M. Canopy Growth's net income of -$128.3M is lower than Cronos Group's net income of $11.4M. Notably, Canopy Growth's price-to-earnings ratio is -- while Cronos Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 1.25x versus 7.28x for Cronos Group. Usually stocks with elevated PS ratios are considered overvalued.

Biocure Technology has a net margin of -203.67% compared to Canopy Growth's net margin of --. Canopy Growth's return on equity of -99.49% beat Biocure Technology's return on equity of --.

Canopy Growth has a consensus price target of $6.15, signalling upside risk potential of 48.91%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Canopy Growth has higher upside potential than Biocure Technology, analysts believe Canopy Growth is more attractive than Biocure Technology.

Canopy Growth has a beta of 1.719, which suggesting that the stock is 71.92% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $63M, which are larger than Biocure Technology quarterly revenues of --. Canopy Growth's net income of -$128.3M is higher than Biocure Technology's net income of --. Notably, Canopy Growth's price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 1.25x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.

TerrAscend has a net margin of -203.67% compared to Canopy Growth's net margin of -31.21%. Canopy Growth's return on equity of -99.49% beat TerrAscend's return on equity of -37.21%.

Canopy Growth has a consensus price target of $6.15, signalling upside risk potential of 48.91%. On the other hand TerrAscend has an analysts' consensus of $2.47 which suggests that it could grow by 154.8%. Given that TerrAscend has higher upside potential than Canopy Growth, analysts believe TerrAscend is more attractive than Canopy Growth.

Canopy Growth has a beta of 1.719, which suggesting that the stock is 71.92% more volatile than S&P 500. In comparison TerrAscend has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Canopy Growth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TerrAscend offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Canopy Growth pays -- of its earnings as a dividend. TerrAscend pays out -- of its earnings as a dividend.

Canopy Growth quarterly revenues are $63M, which are smaller than TerrAscend quarterly revenues of $101.2M. Canopy Growth's net income of -$128.3M is lower than TerrAscend's net income of -$31.6M. Notably, Canopy Growth's price-to-earnings ratio is -- while TerrAscend's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Canopy Growth is 1.25x versus 0.65x for TerrAscend. Usually stocks with elevated PS ratios are considered overvalued.